Cantargia (OMX: CANTA)

Last close As at 27/03/2025

SEK1.49

−0.02 (−1.59%)

Market capitalisation

SEK370m

Cantargia is a clinical-stage biotech company based in Sweden. It is developing two assets against IL1RAP, CAN04 and CAN10. CAN04 is being studied in several solid tumours with a main focus on non-small cell lung cancer (NSCLC) and pancreatic cancer. The most advanced trial is in Phase II.

Latest Insights

View More

Healthcare | Comment

Cantargia (OMX: CANTA) enrols first patient in leukaemia study

Healthcare | Comment

Cantargia (OMX: CANTA) breast cancer study fully recruited

Healthcare | Comment

Cantargia (OMX: CANTA) reports positive CAN10 update

Healthcare | Comment

Cantargia (OMX: CANTA) reports positive CAN10 results

Sector

Healthcare

Equity Analyst

Jyoti Prakash

Jyoti Prakash, CFA

Director, healthcare

Key Management

  • Goran Forsberg

    CEO

Flash note

Healthcare

Cantargia — CAN04 progressing on all fronts

Update

Healthcare

Cantargia — Useful insights from CANOPY-1 data

edison tv

Healthcare

Cantargia – executive interview

edison tv

Healthcare

Cantargia: Edison Open House Healthcare 2022

Update

Healthcare

Cantargia — ‘Post-Novartis’ era has begun

edison tv

Healthcare

Cantargia – executive interview

edison tv

Healthcare

Cantargia – executive interview

Flash note

Healthcare

Cantargia — Novartis’s CANOPY-2 trial disappoints

edison tv

Healthcare

Cantargia – Edison Open House interview

Update

Healthcare

Cantargia — Buoyant on CANFOUR and CANOPY interims

edison tv

Healthcare

Executive interview – Cantargia

Update

Healthcare

Cantargia — Excellent end to the year

Update

Healthcare

Cantargia — Full Phase I data presented at ASCO

edison tv

Healthcare

Executive interview – Cantargia

Update

Healthcare

Cantargia — Nidanilimab transitioning to Phase IIa

Update

Healthcare

Cantargia — CANFOUR interim Phase I presented at ESMO

Update

Healthcare

Cantargia — Phase IIa set to start in Q418

Initiation

Healthcare

Cantargia — Tackling tumour promoting inflammation